Research

Hormonal

Subcutaneous semaglutide at 0.4 mg daily significantly improves histologic resolution of NASH without worsening fibrosis in patients with stage F2 or F3 fibrosis compared to placebo.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks significantly increases the likelihood of NASH resolution without worsening fibrosis compared to placebo. This benefit comes with a higher risk of gastrointestinal side effects, particularly nausea, which often diminishes over time. Patients should be counseled on nutrition and physical activity alongside this treatment.

GoodSupportsHIGH confidence
The percentage of patients in whom NASH resolution was achieved with no worsening of fibrosis was 40% in the 0.1-mg group, 36% in the 0.2-mg group, 59% in the 0.4-mg group, and 17% in the placebo group (P<0.001 for semaglutide 0.4 mg vs. placebo).
Philip N. Newsome et al. · New England Journal of Medicine · 2020

Why this rating

Phase 2, randomized, double-blind, placebo-controlled trial with 320 patients.

Source

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al. · New England Journal of Medicine · 2020

DOI 10.1056/nejmoa2028395

rct · n=320Cited 1,853×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →